CALGARY, Alberta and SAN DIEGO, July 31, 2018 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (TSX:ONC)
(NASDAQ:ONCY), currently developing REOLYSIN® (pelareorep), an intravenously delivered immuno-oncolytic virus turning
cold tumors hot, today announced that it will present at the Canaccord Genuity 38th Annual Growth Conference. The
presentation, by Dr. Matt Coffey, President & CEO of Oncolytics, will take place at 9:30 am ET, on Wednesday, August 8, 2018 in the
Hong Kong Room at the Intercontinental Hotel. The conference takes place on August 8th & 9th in Boston, MA.
A live audio link to the webcast session will be available on the Company's website at http://www.oncolyticsbiotech.com/investor-centre/presentations. It is recommended that listeners
log on 10 minutes in advance of the live session to register and download any necessary software. An audio replay will be
accessible approximately two hours following the presentation on the Oncolytics website.
About Oncolytics Biotech Inc.
Oncolytics is a biotechnology company developing REOLYSIN, also known as pelareorep, an intravenously delivered immuno-oncolytic
virus. The compound induces selective tumor lysis and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" --
through innate and adaptive immune responses to treat a variety of cancers. Oncolytics' clinical development program emphasizes
three pillars: chemotherapy combinations to trigger selective tumor lysis and immuno-therapy and immune modulator (IMiD)
combinations to produce innate and adaptive immune responses. Oncolytics is currently conducting and planning additional studies in
combination with checkpoint inhibitors and targeted and IMiD therapies in solid and hematological malignancies, as it prepares for
a phase 3 registration study in metastatic breast cancer. For further information, please visit: www.oncolyticsbiotech.com.
This press release contains forward-looking statements, within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended and forward-looking information under applicable Canadian securities laws (such forward-looking
statements and forward-looking information are collectively referred to herein as “forward-looking statements”). Forward-looking
statements, including the Company's belief as to the potential and mode of action of REOLYSIN, also known as pelareorep, as a
cancer therapeutic; the collaboration between Merck and USC using pelareorep, including the timing, enrollment and potential
benefits to the Company thereof; and other statements related to anticipated developments in the Company's business and
technologies involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially
from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and
resources to pursue research and development projects, the efficacy of pelareorep as a cancer treatment, the success and timely
completion of clinical studies and trials, the Company's ability to successfully commercialize pelareorep, uncertainties related to
the research and development of pharmaceuticals, uncertainties related to the regulatory process and general changes to the
economic environment. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities
commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are
cautioned against placing undue reliance on forward-looking statements. The Company does not undertake to update these
forward-looking statements, except as required by applicable laws.
